Tocilizumab promotes repair of spinal cord injury by facilitating the restoration of tight junctions between vascular endothelial cells.

ABSTRACT:

Background

Our previous study demonstrated that M1 macrophages could impair tight junctions (TJs) between vascular endothelial cells by secreting interleukin-6 (IL-6) after spinal cord injury (SCI). Tocilizumab, as a humanized IL-6 receptor (IL-6R) monoclonal antibody approved for the clinic, has been applied in the treatment of neurological diseases in recent years, but the treatment effect of Tocilizumab on the TJs restoration of the blood-spinal cord barrier (BSCB) after SCI remains unclear. This study aimed to explore the effect of Tocilizumab on the restoration of TJs between vascular endothelial cells and axon regeneration after SCI.

Methods

In this study, the mouse complete spinal cord crush injury model was used, and Tocilizumab was continuously injected intrathecall

SUBMITTER: Luo Y 

PROVIDER: S-EPMC9830903 | biostudies-literature | 2023 Jan

REPOSITORIES: biostudies-literature